Conference Coverage

Jury still out on effect of systemic psoriasis meds on MI risk


 

EXPERT ANALYSIS AT PDA 2014

References

Dr. Kalb disclosed that he is an investigator and/or consultant for AbbVie, Amgen, Celgene, Dermira, Janssen, Leo, Merck, Pfizer, and Taro. He is also on the dermatology safety monitoring board for ApoPharma and Eli Lilly.

dbrunk@frontlinemedcom.com

On Twitter @dougbrunk

Pages

Recommended Reading

Axial involvement found common in psoriatic arthritis mutilans
MDedge Internal Medicine
First comorbidity guidelines drafted for psoriatic arthritis
MDedge Internal Medicine
First comorbidity guidelines drafted for psoriatic arthritis
MDedge Internal Medicine
Patients with psoriatic arthritis perform accurate joint counts
MDedge Internal Medicine
New guidelines proposed for nail involvement in psoriatic arthritis
MDedge Internal Medicine
Conventional DMARDs may be excluded from psoriatic arthritis enthesitis guidelines
MDedge Internal Medicine
Multicenter cooperative psoriatic arthritis study group formed
MDedge Internal Medicine
Infliximab may carry a higher infection rate in psoriasis patients
MDedge Internal Medicine
Anti-adalimumab antibodies mean poorer outcomes in psoriatic arthritis
MDedge Internal Medicine
Psoriasis patients post above-average cancer rates
MDedge Internal Medicine